ChemicalBook Product Catalog Biochemical Engineering Inhibitors Protein tyrosine kinase /JAK / STAT JAK inhibitors S-Ruxolitinib (INCB018424)

S-Ruxolitinib (INCB018424)

S-Ruxolitinib (INCB018424) Basic information
Product Name:S-Ruxolitinib (INCB018424)
Synonyms:S-Ruxolitinib (INCB018424);S-Ruxolitinib;INCB 18424;1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-;Ruxolitinib (S enantioMer);(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]propanenitrile;RUXOLITINIB S ENANTIOMER;INCB18424;(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (ent-Ruxolitinib)
CAS:941685-37-6
MF:C17H18N6
MW:306.36
EINECS:
Product Categories:Inhibitor;Inhibitors;Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals;JAK;STAT
Mol File:941685-37-6.mol
S-Ruxolitinib (INCB018424) Structure
S-Ruxolitinib (INCB018424) Chemical Properties
Melting point 138-143oC
density 1.40±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
pka11.63±0.50(Predicted)
color White
Safety Information
MSDS Information
S-Ruxolitinib (INCB018424) Usage And Synthesis
Uses(3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile is a newly developed JAK2 inhibitor therapy aimed to improve MPN-associated splenomegaly and systemic symptoms. The opposite enantiomer of Ruxolitinib (R702000).
Biological Activitys-ruxolitinib is the chirality of incb018424, is a potent and selective small-molecule janus kinase 1 (jak1) and jak2 inhibitor. it was initially developed to target the constitutive activation of the jak-stat pathway. janus kinases (jaks) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. ruxolitinib maintains its anti-jak activity by competitive inhibition of the atp-binding catalytic site of the kinase domain. ruxolitinib is well absorbed at >95%. exposure of jak2v617f-positive ba/f3 cells to ruxolitinib iss shown to result in reduced cellular proliferation.ruben a. mesa, uma yasothan, peter kirkpatrick. ruxolitinib. nature reviews drug discovery. 2012; 11: 103-104john mascarenhas, ronald hoffman. ruxolitinib: the first fda approved therapy for the treatment of myelofibrosis. clinical cancer research. 2012; 18(11): 3008 - 3014
targetJAK1
S-Ruxolitinib (INCB018424) Preparation Products And Raw materials
Olaparib Selonsertib 1H-Pyrazole-1-propanenitrile, 4-(6-amino-5-formyl-4-pyrimidinyl)-β-cyclopentyl-, (βR)- 1H-Pyrazole-1-propanenitrile, β-(2-hydroxycyclopentyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)- 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-[7-(hydroxyMethyl)-7H-pyrrolo[2,3-d]pyriMidin-4-yl]-,(βR)- 1H-Pyrazole-1-propanamide, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)- VE 822 Dasatinib 1H-Pyrazole-1-propanoic acid, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)- Linsitinib 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-[7-[[2-(triMethylsilyl)ethoxy]Methyl]-7H-pyrrolo[2,3-d]pyriMidin-4-yl]- ABT-199 1H-Pyrazole-1-propanamide, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 4-(1H-PYRAZOL-4-YL)-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE Ruxolitinib phosphate Bortezomib 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Zanubrutinib
Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.